Fumaderm (dimethyl fumarate) / Biogen 
Welcome,         Profile    Billing    Logout  
 12 Diseases   4 Trials   4 Trials   312 News 


«12345»
  • ||||||||||  Review, Journal:  Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. (Pubmed Central) -  Mar 29, 2020   
    The results indicated that brodalumab had a similar probability of response to ixekizumab, secukinumab and infliximab and a higher probability of response than ustekinumab, adalimumab, etanercept, apremilast, dimethyl fumarate and placebo...Brodalumab is recommended as an option for treating adults with severe plaque psoriasis (defined by a total Psoriasis Area and Severity Index score of 10 or more and a Dermatology Life Quality Index score of more than 10) who have not responded to other systemic non-biological therapies. Brodalumab should be stopped at 12 weeks if the psoriasis has not responded adequately.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Journal:  Analyzing cysteine site neighbors in proteins to reveal dimethyl fumarate targets. (Pubmed Central) -  Mar 9, 2020   
    Furthermore, neighborhood composition has shown itself to be a network-type attribute that is endowed with remarkable predictive power when distinct classification algorithms are employed. In conclusion, when adopted in combination with other target identification/validation approaches, methods that are based on the analysis of cysteine site neighbors in proteins should provide useful information by which to decipher the mode of action of DMF-based drugs.
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Clinical, Journal, Monotherapy:  Switch of psoriasis therapy from a fumaric acid ester mixture to dimethyl fumarate monotherapy: Results of a prospective study. (Pubmed Central) -  Feb 25, 2020   
    In conclusion, when adopted in combination with other target identification/validation approaches, methods that are based on the analysis of cysteine site neighbors in proteins should provide useful information by which to decipher the mode of action of DMF-based drugs. The results show that it is possible to switch psoriasis patients under stable therapy with the FAE mixture to the DMF drug directly and without interruption.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Dimethyl Fumarate Ameliorates Disease Severity in a Mouse Model of Chronic Graft-Versus-Host Disease. (World Center Marriott - Palms & Cypress Foyers) -  Jan 14, 2020 - Abstract #TCTASTCTCIBMTR2020TCT_1031;    
    Conclusion DMF has already been shown to be safe and effective in autoimmune diseases. Our studies indicate that DMF could have therapeutic potential in the setting of cGvHD as a selective inhibitor of activated, alloreactive T cells.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Journal:  Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex. (Pubmed Central) -  Jan 1, 2020   
    We show that DMF blocks IRAK4-MyD88 interactions and IRAK4-mediated cytokine production in a cysteine 13-dependent manner. Our studies thus identify a proteomic hotspot for DMF action that constitutes a druggable protein-protein interface crucial for initiating innate immune responses.
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Clinical, Journal:  Fumaric acid ester-induced T cell lymphopenia in the real-life treatment of psoriasis. (Pubmed Central) -  Dec 21, 2019   
    We therefore suggest optimizing pharmacovigilance by additionally monitoring CD4 and CD8 T-cell counts at regular intervals, especially in patients of middle to older age. Thus, further prospective studies are needed to establish evidence-based recommendations to guide dermatologists in the management of psoriasis patients who are taking FAEs and who develop low absolute T-cell counts.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Journal, Oncolytic Virus:  Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition. (Pubmed Central) -  Sep 18, 2019   
    The ability of DMF to enhance viral spread results from its ability to inhibit type I interferon (IFN) production and response, which is associated with its blockade of nuclear translocation of the transcription factor nuclear factor κB (NF-κB). This study demonstrates that unconventional application of U.S. Food and Drug Administration-approved drugs and biological agents can result in improved anticancer therapeutic outcomes.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
    Preclinical, Journal:  Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model. (Pubmed Central) -  May 24, 2019   
    ...Particularly, dimethyl fumarate (DMF), which is clinically approved for the treatment of multiple sclerosis and psoriasis, strongly cooperated with 1,25D3, PRI-5100 (19-nor-1,25D2; paricalcitol) and PRI-5202 (a double-point modified 19-nor analog of 1,25D2)...Importantly, using a xenograft mouse model we demonstrated that co-administration of PRI-5202 and DMF resulted in a marked cooperative inhibition of human AML tumor growth without inducing treatment toxicity. Collectively, our findings provide a rationale for clinical testing of low-toxic VDD/DMF combinations as a novel approach for differentiation therapy of AML.
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Review, Journal:  A review of the mechanisms of action of dimethylfumarate (DMF) in the treatment of psoriasis. (Pubmed Central) -  May 22, 2019   
    There is a growing body of evidence to support the notion that DMF/MMF may also exert effects on granulocytes and non-immune cell lineages including keratinocytes and endothelial cells. A better understanding of the multiple molecular mechanisms involved in the cellular action of FAEs will help to adapt and further improve the use of such small molecules for the treatment of psoriasis and other chronic inflammatory diseases.
  • ||||||||||  Skilarence (dimethyl fumarate) / Almirall
    Trial completion, Enrollment change:  LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) -  Dec 4, 2015   
    P3,  N=839, Completed, 
    Initiation date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed | N=690 --> 839
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Fumaderm (dimethyl fumarate) / Biogen
    Trial completion, Trial primary completion date:  IIT6: Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design (clinicaltrials.gov) -  Oct 17, 2015   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed | N=690 --> 839 Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014
  • ||||||||||  Skilarence (dimethyl fumarate) / Almirall
    Enrollment closed:  LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) -  Jun 10, 2015   
    P3,  N=690, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2014 Recruiting --> Active, not recruiting
  • ||||||||||  dimethyl fumarate controlled release (FP 187) / Forward Pharma
    Trial initiation date, Trial primary completion date, Head-to-Head:  Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) -  Mar 7, 2015   
    P3,  N=500, Not yet recruiting, 
    Trial primary completion date: Sep 2014 --> Sep 2015 Initiation date: Sep 2013 --> Jun 2015 | Trial primary completion date: Aug 2014 --> Jun 2017
  • ||||||||||  Fumaderm (dimethyl fumarate) / Biogen
    Trial completion:  FumaCLE: Efficacy and Safety of Fumaric Acid Esters (Fumaderm (clinicaltrials.gov) -  Feb 26, 2014   
    P2,  N=11, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  Skilarence (dimethyl fumarate) / Almirall
    Enrollment open:  LAS41008 in Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) -  Jan 20, 2013   
    P3,  N=690, Recruiting, 
    N=750 --> 500 Not yet recruiting --> Recruiting